Skip to content

IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer

Intraoperative Radiotherapy(IORT) Followed by Concurrent Chemoradiotherapy(CCRT) or Stereotactic Radiotherapy(SBRT) for Locally Advanced Pancreatic Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02734680
Acronym
IFCSLAPC
Enrollment
70
Registered
2016-04-12
Start date
2016-02-29
Completion date
2019-02-28
Last updated
2017-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

Pancreatic cancer, Intraoperative radiotherapy(IORT), Postoperative radiochemotherapy

Brief summary

The purpose of this study is to find the best model of combination of intraoperative radiotherapy(IORT) and postoperative radiochemotherapy for pancreatic cancer.

Detailed description

The trial is funded by Cancer Foundation of China. The trial is prepared to be registered on the clinicaltrail.gov. Quality assurance plan: every participant is enrolled or excluded by two practiced investigators. And two investigators participated in all steps of the trail, including the record of the data, and the investigators will compare the data. If the data is consistent, the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the workers of research and financial department of National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences. Data check: the investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry. Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms. Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information, and normal ranges if relevant. Standard Operating Procedures to address registry operations and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators. Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 70 participants to take part in the trail. The investigators can recruit about 35 participants every year according to previous experiences, so the investigators should recruit at least for two years. Plan for missing data: the investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results. Statistical analysis plan: Kaplan-Meier method would be used to analyze the difference of survival time between the two groups, and the local control rate of the two groups would be compared by chi square test. Statistical analyses would be performed by using IBM SPSS Statistics(version 20; IBM, Chicago, USA). The level of significance is defined as P \< 0.05.

Interventions

RADIATIONConcurrent chemoradiotherapy(CCRT)

Radiation and take gemcitabine(GEM)

RADIATIONStereotactic Radiotherapy(SBRT)

Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)

DRUGS-1

Taking S-1 orally after radiation

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed as locally advanced pancreatic cancer. * Cannot be treated by surgical resection.

Exclusion criteria

* Treated by chemotherapy or radiotherapy before. * With distant organ metastasis. * Cannot tolerate surgery (Intraoperative radiotherapy)

Design outcomes

Primary

MeasureTime frameDescription
Overal survival2 yearsOS

Secondary

MeasureTime frameDescription
Disease-specific survival2 yearsDSS
Progression-free survival2 yearsPFS
Local control rate2 yearsLCR

Countries

China

Contacts

Primary ContactYingtai Chen, PhD
yingtai.chen@hotmail.com+8618600258827
Backup ContactShuisheng Zhang, M.D.
thelifeofwater@126.com+8618001302322

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026